During the past decade, Atlanta Cancer Care - Stockbridge conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Atlanta Cancer Care - Stockbridge" are "Breast Cancer" (1 trials), "Genes, BRCA 1" (1 trials) and "Locally Advanced or Metastatic Solid Tumors" (1 trials). Many other conditions were trialed in "Atlanta Cancer Care - Stockbridge" in a lesser frequency.

Most popular intervention types in "Atlanta Cancer Care - Stockbridge" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Avelumab" (1 trials), "Capecitabine" (1 trials), "Eribulin" (1 trials), "Gemcitabine" (1 trials) and "Sacituzumab govitecan" (1 trials). Other intervention names were less common.

The vast majority of trials in "Atlanta Cancer Care - Stockbridge" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Atlanta Cancer Care - Stockbridge". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Atlanta Cancer Care - Stockbridge, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Atlanta Cancer Care - Stockbridge, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".